Urine-based Malaria Test (UMT)
Fyodor holds a worldwide exclusive license to the urine-based malaria test (UMT) technology developed at Johns Hopkins University. Under the terms of the license agreement, Fyodor is responsible for the final development of the product, as well as regulatory, manufacturing, and marketing activities. The preclinical validation studies of the UMT are currently underway in a three-way collaboration involving Fyodor, Johns Hopkins and the US Army–Walter Reed Army Institute of Research (US Army–WRAIR).

Yeast-derived Artemisinin (YAT)
Fyodor is developing a novel microbial engineering platform technology for the production of artemisinin in recombinant yeast licensed from the National Research Council of Canada. Using multiple expression systems, Fyodor is developing yeast systems that produce up to gram quantities of recombinant artemisinin, the highly-effective first-line treatment for malaria. Recently, additional uses for artemisinin were discovered, including for the treatment of various types of cancers, hepatitis C and as a broad antiviral agent.